[go: up one dir, main page]

ES2148184T3 - Utilizacion del acido 9-cis retinoico, sus sales y esteres, para el tratamiento de tumores epiteliales. - Google Patents

Utilizacion del acido 9-cis retinoico, sus sales y esteres, para el tratamiento de tumores epiteliales.

Info

Publication number
ES2148184T3
ES2148184T3 ES93100257T ES93100257T ES2148184T3 ES 2148184 T3 ES2148184 T3 ES 2148184T3 ES 93100257 T ES93100257 T ES 93100257T ES 93100257 T ES93100257 T ES 93100257T ES 2148184 T3 ES2148184 T3 ES 2148184T3
Authority
ES
Spain
Prior art keywords
rethinoic
cis
esters
salts
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93100257T
Other languages
English (en)
Inventor
Werner Bollag
Joseph Francis Grippo
Arthur Levin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HOFFMANN LA ROCHE
F Hoffmann La Roche AG
Original Assignee
HOFFMANN LA ROCHE
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HOFFMANN LA ROCHE, F Hoffmann La Roche AG filed Critical HOFFMANN LA ROCHE
Application granted granted Critical
Publication of ES2148184T3 publication Critical patent/ES2148184T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Fats And Perfumes (AREA)

Abstract

EL ACIDO 9-CIS RETINOICO, SUS SALES Y ESTERES SE PUEDEN UTILIZAR PARA EL TRATAMIENTO DE LESIONES EPITELIALES MALIGNAS Y PREMALIGNAS, LOS DAÑOS FOTOELECTRICOS EN LA PIEL Y LOS TRASTORNOS ORIGINADOS POR UNA PRODUCCION EXCESIVA DE SEBO Y LA PSORIASIS.
ES93100257T 1992-01-22 1993-01-11 Utilizacion del acido 9-cis retinoico, sus sales y esteres, para el tratamiento de tumores epiteliales. Expired - Lifetime ES2148184T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82378692A 1992-01-22 1992-01-22
US82392892A 1992-01-22 1992-01-22
US82374192A 1992-01-22 1992-01-22
US82464792A 1992-01-23 1992-01-23

Publications (1)

Publication Number Publication Date
ES2148184T3 true ES2148184T3 (es) 2000-10-16

Family

ID=27505866

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93100257T Expired - Lifetime ES2148184T3 (es) 1992-01-22 1993-01-11 Utilizacion del acido 9-cis retinoico, sus sales y esteres, para el tratamiento de tumores epiteliales.

Country Status (20)

Country Link
EP (1) EP0552624B1 (es)
JP (1) JP3631259B2 (es)
CN (2) CN1068200C (es)
AT (1) ATE194077T1 (es)
AU (1) AU667864B2 (es)
CA (1) CA2087251C (es)
CY (1) CY2251B1 (es)
CZ (1) CZ282548B6 (es)
DE (1) DE69328910T2 (es)
DK (1) DK0552624T3 (es)
ES (1) ES2148184T3 (es)
GR (1) GR3034323T3 (es)
HU (2) HU212734B (es)
IL (1) IL104450A (es)
NO (1) NO302274B1 (es)
NZ (1) NZ245686A (es)
PH (1) PH31621A (es)
PT (1) PT552624E (es)
RU (1) RU2119333C1 (es)
TW (1) TW226329B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE617614T1 (de) 1991-12-18 1995-06-08 Baylor College Of Medicine, Houston, Tex. Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen.
US7056954B2 (en) 1991-12-18 2006-06-06 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US5968989A (en) 1991-12-18 1999-10-19 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US5962731A (en) * 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5549888A (en) * 1994-01-31 1996-08-27 Procter & Gamble Aqueous topical anti-acne compositions of low pH
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
CA2218685A1 (en) * 1995-04-21 1996-10-24 Ligand Pharmaceuticals Incorporated Inhibition of apoptosis in cells expressing fas-ligand following activation
DE19523079A1 (de) * 1995-06-26 1997-01-02 Basf Ag Ester und Amide der 9(Z)-Retinsäure
EP0788353A1 (en) 1995-09-18 1997-08-13 Ligand Pharmaceuticals, Inc. Ppar gamma antagonists for treating obesity
DE69631541T2 (de) * 1995-09-18 2004-12-23 Ligand Pharmaceuticals, Inc., San Diego Behandlung von NIDDM (nicht-insulinabhängigem Diabetes Mellitus)
TW442459B (en) * 1996-04-15 2001-06-23 Hoffmann La Roche Retinoid compounds, pharmaceutical composition comprising same and process for the preparation thereof
FR2765480B1 (fr) 1997-07-07 1999-09-10 Oreal Utilisation pour le revetement des matieres keratiniques d'un materiau polymerique hybride ; compositions cosmetiques ou dermatologiques
AU8588798A (en) 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
AU1707599A (en) * 1998-03-20 1999-10-18 Warner-Lambert Company Retinoid-glitazone combinations
AU757729B2 (en) 1999-04-07 2003-03-06 Sankyo Company Limited Amine derivatives
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
WO2003086374A1 (en) * 2002-04-05 2003-10-23 University Of Utah Research Foundation Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2
AU2003270414A1 (en) * 2002-09-06 2004-03-29 Oregon Health And Science University Effect of vitamin a gel on paranasal sinus mucosal regeneration
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
JP4825957B2 (ja) * 2005-03-29 2011-11-30 国立大学法人 鹿児島大学 抗腫瘍剤
AU2009352678B2 (en) 2009-09-15 2015-05-21 Eluminex Biosciences (Suzhou) Limited Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
WO2011129765A1 (en) * 2010-04-16 2011-10-20 Davos Life Science Pte. Ltd. Synergistic interaction of at least one vitamin e component and tyrosinase inhibitors for dermatological applications
SG184971A1 (en) 2010-04-19 2012-11-29 Quadra Logic Tech Inc Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
CA2865935C (en) 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
JP6182728B2 (ja) * 2012-11-02 2017-08-23 国立大学法人名古屋大学 幹細胞を標的とした薬効及び毒性の評価法
WO2022051831A1 (pt) 2020-09-11 2022-03-17 Chemyunion Ltda. Composição, uso de composição, método cosmético e método para modular a produção de sebo
WO2023168608A1 (en) * 2022-03-08 2023-09-14 Mastery Biotech Co., Ltd. Pharmaceutical composition including retinoic acid and carbohydrate and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA713539B (en) * 1970-06-23 1972-02-23 Hoffmann La Roche Pharmaceutical compositions
AU610587B2 (en) * 1987-04-06 1991-05-23 Daltex Medical Sciences, Inc. Treatment of aged skin with oral 13-cis-retinoic acid
US4994491A (en) * 1988-12-14 1991-02-19 Molecular Design International Dermal uses of trans-retinoids for the treatment of cancer
LU86969A1 (fr) * 1987-08-12 1989-03-08 Oreal Association de derives de pyrimidine et de retinoides en composants separes pour induire et stimuler la croissance des cheveux et diminuer leur chute
DE617614T1 (de) * 1991-12-18 1995-06-08 Baylor College Of Medicine, Houston, Tex. Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen.

Also Published As

Publication number Publication date
PT552624E (pt) 2000-10-31
NO302274B1 (no) 1998-02-16
DK0552624T3 (da) 2000-09-25
CN1155376C (zh) 2004-06-30
HU211167A9 (en) 1995-11-28
AU667864B2 (en) 1996-04-18
ATE194077T1 (de) 2000-07-15
DE69328910T2 (de) 2001-01-11
CA2087251C (en) 2003-06-24
JPH06107542A (ja) 1994-04-19
IL104450A (en) 1997-03-18
IL104450A0 (en) 1993-05-13
CZ372892A3 (en) 1993-12-15
JP3631259B2 (ja) 2005-03-23
HU212734B (en) 1996-10-28
EP0552624B1 (en) 2000-06-28
CN1068200C (zh) 2001-07-11
DE69328910D1 (de) 2000-08-03
HUT63053A (en) 1993-07-28
PH31621A (en) 1999-01-12
RU2119333C1 (ru) 1998-09-27
CZ282548B6 (cs) 1997-08-13
CN1074826A (zh) 1993-08-04
CA2087251A1 (en) 1993-07-23
NZ245686A (en) 1995-05-26
AU3186193A (en) 1993-07-29
GR3034323T3 (en) 2000-12-29
EP0552624A1 (en) 1993-07-28
CY2251B1 (en) 2003-07-04
HU9300116D0 (en) 1993-04-28
TW226329B (es) 1994-07-11
CN1256916A (zh) 2000-06-21
NO930206D0 (no) 1993-01-21
NO930206L (no) 1993-07-23

Similar Documents

Publication Publication Date Title
ES2148184T3 (es) Utilizacion del acido 9-cis retinoico, sus sales y esteres, para el tratamiento de tumores epiteliales.
ES2159851T3 (es) Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.
AR009507A1 (es) Utilizacion de retinoides
RU93005355A (ru) Фармакологические композиции
ES2094033T3 (es) Composicion cosmetica y/o dermatologica que contiene derivados de acido salicilico y procedimiento de solubilizacion de estos derivados.
ES2089309T3 (es) Preparacion y empleo de sales de los enantiomeros puros del acido alfa-lipoico.
FI863976A0 (fi) Terapeutisk komposition.
MC2078A1 (fr) Emploi d'alezastine comme matiere active contre le psoriasis et des maladies inflammatoires
ES2062181T3 (es) Procedimiento para la obtencion de pirazol y sus derivados.
KR930016100A (ko) 약제학적 조성물
ES2053856T3 (es) Derivados del acido 4-quinoleino carboxilico utiles para el tratamiento de enfermedades de la piel y del muco-epitelio.
AR203047A1 (es) Procedimiento para preparar derivados del acido 2-(1-piperazinil-5 8-dihidro-5-oxo-pirido<2,3-d>-pirimidin-6-carboxilico
IT1129250B (it) Procedimento per la produzione di un vettore di trasferimento del ona e per il suo impiego nella preparazione della proinsulina e della pre proinsulina umana
DOP1983004137A (es) Proceso para aumentar la efectividad del bagazo como una fuente de energia.
ES544664A0 (es) Procedimiento para el diagnostico in vitro del sexo
ATE113209T1 (de) Verwendung von 5-amino-salicylsäure für die behandlung von hautkrankheiten.
ATE46817T1 (de) Verwendung von 6-(z)- bzw. 2-(z)-konfigurierten 3,7,11-trimethyl-dodeca-2,6,10-trien-1-olen als bakteriostatikum in kosmetischen produkten.
ES2054941T3 (es) 4-sulfonilamino-2-acinil-1,2,4-triazol-3-onas substituidas, procedimientos asi como productos intermedios para su fabricacion y su utilizacion como herbicidas.
ES2111891T3 (es) Empleo de l-carnitina o acil l-carnitinas y valproato para tratar trastornos epilepticos.
ES2096724T3 (es) Resolucion optica de acido (+/-)-2-(4-isobutilfenil)propionico.
ATE91899T1 (de) Verwendung eines ornithin-decarboxylateinhibitors zur herstellung eines praeparats fuer die behandlung, zusammen mit lak-zellen und interleukin-2, von tumoren.
ES2032285T3 (es) Procedimiento para la isomerizacion de esteres del acido 2-pentenico en esteres del acido 3-pentenico.
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
ES2087241T3 (es) Uso de retinoides para minimizar el daño en la piel.
FR882973A (fr) Procédé d'amenée de matière fondue au pot de presse

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 552624

Country of ref document: ES